Table 4 Patient characteristics for patients with any failures in elective nodal regions
Patient with ENF | T-Stage | N-Stage | Pathologic diagnosis | Primary tumor location | Dose (Gy) | Chemotherapay | Site of failure | Dose to failure site (Gy) |
|---|---|---|---|---|---|---|---|---|
1 | 2 | 1 | Squamous | Left hilum | 60 | None | Right supraclavicular* | < 1.0 |
2 | 4 | 3 | Adenocarcinoma | Left lower lobe | 63 | Concurrent carboplatin/paclitaxel | Ipsilateral mediastinum | 22.5 |
3 | 2/1 | 0/0 | Adenocarcinoma | Left lower lobe/right upper lobe†| 66 | None | Left hilum, Left supraclavicular, Right supraclavicular | 23.3, 24.4, 44.3 |
4 | 2 | 3 | Adenocarcinoma | Right upper lobe | 60 | Induction and concurrent carboplatin/paclitaxel | Right supraclavicular* | 10.7 |
5 | 2 | 3 | Squamous | Right upper lobe, contralateral mediastinum, right hilum | 63 | Concurrent carboplatin/paclitaxel | Left hilum | 30.4 |